Baxter Acquires Biotech Co. for $70M

Apr 03, 2014

Baxter International

Baxter International Inc. has agreed to acquire privately held Chatham Therapeutics for an initial payment of $70 million, giving Baxter access to developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.

In May 2012, Baxter and Chatham entered into a collaboration to evaluate Chatham's Biological Nano Particle platform as a potential treatment for hemophilia B, known as BAX 335, which is currently in a Phase I/II study. As a result of this acquisition, Baxter obtains broad access to Chatham's gene therapy platform, including the previously partnered hemophilia B program, a preclinical hemophilia A program, and the potential future application to additional hemophilia treatments.

Last week, Baxter announced plans to create two separate, independent healthcare companies - one focused on developing and marketing biopharmaceuticals and the other on medical products.

Read the Baxter/Chatham aquisition press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments